David B. Volkin
Affiliations: | Pharmaceutical Chemistry | University of Kansas, Lawrence, KS, United States |
Area:
PharmacyWebsite:
http://distinguishedprofessors.ku.edu/professor/volkin-dGoogle:
"David B. Volkin"Bio:
Volkin, David B. (David Bernard) The upper limit of protein thermostability Thesis (Ph. D.)--Massachusetts Institute of Technology, Dept. of Applied Biological Sciences, 1989
Mean distance: (not calculated yet)
Parents
Sign in to add mentorAlexander M. Klibanov | grad student | 1989 | MIT | |
(The upper limit of protein thermostability.) |
Children
Sign in to add traineeMohammad A. Alsenaidy | grad student | 2013 | University of Kansas |
Ranajoy Majumdar | grad student | 2014 | University of Kansas |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Caringal RT, Hickey JM, Sharma N, et al. (2024) A Combined LC-MS and Immunoassay Approach to Characterize Preservative-Induced Destabilization of Human Papillomavirus Virus-like Particles Adsorbed to an Aluminum-Salt Adjuvant. Vaccines. 12 |
Kumru OS, Bajoria S, Kaur K, et al. (2023) Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD). Human Vaccines & Immunotherapeutics. 19: 2264594 |
Kumru OS, Sanyal M, Friedland N, et al. (2023) Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 spike ferritin nanoparticle vaccine antigen produced from two different cell lines. Vaccine |
Bajoria S, Kumru OS, Doering J, et al. (2023) Nanoalum Formulations Containing Aluminum Hydroxide and CpG 1018 Adjuvants: The Effect on Stability and Immunogenicity of a Recombinant SARS-CoV-2 RBD Antigen. Vaccines. 11 |
Kumru OS, Sanyal M, Friedland N, et al. (2023) Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines. Biorxiv : the Preprint Server For Biology |
Bajoria S, Kaur K, Kumru OS, et al. (2022) Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvants. Human Vaccines & Immunotherapeutics. 2079346 |
Sawant N, Joshi SB, Weis DD, et al. (2021) Interaction of Aluminum-adjuvanted Recombinant P[4] Protein Antigen With Preservatives: Storage Stability and Backbone Flexibility Studies. Journal of Pharmaceutical Sciences |
Kumar P, Shukla RS, Patel A, et al. (2021) Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries. Human Vaccines & Immunotherapeutics. 1-13 |
Sawant N, Kaur K, Holland DA, et al. (2020) Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens. Journal of Pharmaceutical Sciences |
Kaur K, Xiong J, Sawant N, et al. (2020) Mechanism of thimerosal-induced structural destabilization of a recombinant rotavirus P[4] protein antigen formulated as a multi-dose vaccine. Journal of Pharmaceutical Sciences |